Real-world outcomes of generic elexacaftor/tezacaftor/ivacaftor (gETI) in South Africans (SA) with CF using standard versus clarithromycin-boosted gETI, modulator-sparing strategies to reduce cost

RECOMMENDED

Pulmonary Fibrosis

The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

★ 2 Recommended by Dr Martin Frey, Faculty Member

Lancet Respir Med

Burgel PR, Sermet-Gaudelus I, Girodon E, Durieu I, Houdouin V, Audousset C, Macey J, Grenet D, Porzio M, Murris-Espin M, Reix P, Baravalle M, Belleguic C, Mely L, Verhille J, Weiss L, Reynaud-Gaubert M, Mittaine M, Hamidfar R, Ramel S, Cosson L, Douvry B, Danner-Boucher I, Foucaud P, Roy C, Burnet E, Raynal C, Audrezet MP, Da Silva J, Martin C, French Cystic Fibrosis Reference Network study group

doi: 10.1016/S2213-2600(24)00208-X

Pulmonary Fibrosis

Real-World Effectiveness and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients with Phe508del -Gating and -Residual Function Genotypes

Respir Med

Salvatore D, Iacotucci P, Pepe A, Terminiello A, Majo F, Carnovale V, Vitullo P, Messore B, Parisi GF, Calderazzo MA, Leonetti G, Terlizzi V

doi: 10.1016/j.rmed.2025.108221

RECOMMENDED

Pulmonary Fibrosis

First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

J Cyst Fibros

Bonnel AS, Bihouée T, Ribault M, Driessen M, Grèvent D, Foissac F, Truong NH, Benhamida M, Arnouat B, Borghese R, Chedevergne F, Couderc-Kohen L, da Silva J, Grenet D, Houdouin V, Le A, Marchal S, Deneuville E, Pouradier D, Rousseau V, Treluyer JM, Francart A, Steffann J, Reix P, Benaboud S, Mamzer MF, Ville Y, Martin C, Burgel PR, Sermet-Gaudelus I, MODUL-CF study group

doi: 10.1016/j.jcf.2025.03.009

RECOMMENDED

Pulmonary Fibrosis

Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

★ 2 Recommended by Dr Martin Frey, Faculty Member

Lancet Respir Med

Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A

doi: 10.1016/S2213-2600(24)00411-9

RECOMMENDED

Pulmonary Fibrosis

Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24 months of lumacaftor ivacaftor therapy based on real-world data

★ 1 Recommended by Dr Martin Frey, Faculty Member

Sci Rep

Imrei M, Kéri AF, Gács É, Gönczi I, Meláth M, Kosaras É, Demeter B, Péterfia C, Vass K, Székely G, Ocskay K, Párniczky A

doi: 10.1038/s41598-025-86010-1

Pulmonary Fibrosis

LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis

J Cyst Fibros

Vega-Hernandez G, MacGregor G, Wilfin A, Adams F, Haugh C, Baxter CA, Wöhling H, Clarke SL, Charman SC, Carr SB

doi: 10.1016/j.jcf.2025.04.012

RECOMMENDED

Pulmonary Fibrosis

Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Respir Res

Gramegna A, Cimino G, Cipolli M, Gandini G, Calderazzo MA, Profiti A, Piedepalumbo F, Blasi F

doi: 10.1186/s12931-024-03089-2

Pulmonary Fibrosis

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study

J Clin Med

Lucca F, Meneghelli I, Tridello G, Buniotto F, Cucchetto G, Volpi S, Pintani E, Bezzerri V, Cipolli M

doi: 10.3390/jcm14124335

ERS 2024

Asthma

Related content

The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

Real-World Effectiveness and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients with Phe508del -Gating and -Residual Function Genotypes

First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study

Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24 months of lumacaftor ivacaftor therapy based on real-world data

LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis

Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study

BEHAVE: Benralizumab reduces exacerbations and improves asthma control in real-world patients with severe asthma